---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-042955"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:35:02.373598+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q1 EPS $2.96 (+5%), rev $998M (+4%); raises FY25 revenue & EPS outlook

## Summary
- Q1 revenue $998M (+4% reported, +5% organic); EPS $2.96 (+5%, +7% comparable).
- CAG Diagnostics recurring revenue +3% reported, +4.5% organic; VetLab consumables organic +10%.
- Launched IDEXX Cancer Dx for early canine lymphoma detection in North American reference labs.
- FY25 revenue guidance raised to $4,095M-$4,210M; EPS guidance raised to $11.93-$12.43 ($0.19 increase).
- FY25 organic revenue growth outlook maintained at 6%-9%; comparable EPS growth maintained at 8%-12%.

## SEC filing metadata
- accession: 0001104659-25-042955
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000110465925042955/0001104659-25-042955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000110465925042955/tm2513742d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-042955
- JSON: https://secwatch.observer/filing/0001104659-25-042955.json
- Plain text: https://secwatch.observer/filing/0001104659-25-042955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.